OKYO Pharma Ltd — Director's Dealing 2022

May 16, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OKYO Pharma Ltd (OKYO)
CIK: 0001849296
Period of Report: 2022-05-16

Reporting Person: Simon Willy Jules (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$0.0588	2025-06-07	Ordinary Shares (2000000)		Direct

Footnotes

F1: 25% will vest each year on January 9, beginning on June 7, 2018.